Vantictumab, formerly known as OMP18R5, represents the novel cloned agent designed with specifically inhibit osteopontin molecule 18R5. Such therapy is currently Vantictumab for in vitro assays studied by Amgen regarding potential treatments in various orthopedic conditions, particularly conditions involving excessive osseous breakdown. Preclinical